|
|
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中
, ~1 e% C% ?: LWhole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)
+ f% Z$ ], ^5 q |4 A. A6 C/ c, Z+ [5 c% G7 p) l
Adjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
( q! P3 f0 [! {9 |, W. M
5 \+ Z* }* @6 R/ l% d9 D8 }GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)" o3 c9 _! k: A! |# A/ g5 z
Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)* Z, \# }' V4 N; N1 p' {
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中), ~1 _3 s3 L3 h2 y3 S: X) M
Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中)
9 ^7 t5 R7 A2 s6 jTQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)) T7 M# c6 ^0 J
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)
" P5 X( f$ ?( `# D" M4 e) w- N, TMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
! X' r1 P5 ~) ?Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) |
|
发表于 
楼主
